Both autoimmune and autoinflammatory diseases (AIDs) are characterised by bouts of hyperactivation of immune reactions towards host tissues. While the false immune stress in autoimmune disorders is due to the failure of the adaptive immune system to recognize ‘self’ and ‘non-self’, the innate immune system is provoked in conditions of autoinflammation. Despite the different pathways taken by the two types of disorders, they share overlapping mechanisms at the molecular level. For example, cytokine IL-1? can mediate the inflammation in innate immunity and promote the proliferation of T and B cells in adaptive immunity.
The rising incidence of autoimmune and autoinflammatory diseases across the world cannot simply be explained by genetic predisposition and better screening programmes. Remarkable environmental alterations and the upsurge in pollution, sleep deprivation, obesity, and a sedative lifestyle are compounding stressors that challenge our immune system. Consequently, patients’ suffering persists, and the economic burden soars.
This is a comprehensive collection of cutting-edge research articles that delve into identifying, validating, and applying biomarkers in diagnosing and managing autoimmune and autoinflammatory disorders. By presenting a curated selection of peer-reviewed research works, the objective of this collection is to provide healthcare professionals and researchers with critical insights into biomarkers in autoimmune and autoinflammatory disease, bringing profound implications for clinical practice and research. By integrating biomarker data into diagnostic and therapeutic strategies, healthcare providers can achieve more precise and personalized patient care. Additionally, these insights can guide future efforts in the development of novel treatment and diagnostic tools.
This collection is intended for a wide audience, including immunologists, rheumatologists, dermatologists, clinical researchers, and medical students. It will serve as a valuable resource for pharmaceutical companies and policymakers involved in healthcare planning and disease management.
This collection welcomes original research or review articles investigating autoimmune/autoinflammatory diseases and related inflammatory conditions, including (but not limited to):
- Novel biomarker discovery and validation for specific diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and ocular conditions.
- Discovery of novel genetic variants associated with disease initiation and/or progression.
- Development of biomarker panels for more accurate and early diagnosis.
- Mechanistic insights into biomarker function.
- Identification of specific biomarkers that can distinguish between different autoimmune and autoinflammatory diseases.
- Discovery of biomarkers that correlate with disease activity and severity.
- Discovery of biomarkers with therapeutic potential, especially with durable efficacy in controlling chronic conditions.
- Predictive biomarkers for treatment responses and disease progression.
- Technological advancements in biomarker detection.
Dr. Jian Liu declares the following conflicts of interest related to this research topic:
Shares in Cirrus Therapeutics and is an inventor listed on the WIPO patent WO2023089151A1.
Both autoimmune and autoinflammatory diseases (AIDs) are characterised by bouts of hyperactivation of immune reactions towards host tissues. While the false immune stress in autoimmune disorders is due to the failure of the adaptive immune system to recognize ‘self’ and ‘non-self’, the innate immune system is provoked in conditions of autoinflammation. Despite the different pathways taken by the two types of disorders, they share overlapping mechanisms at the molecular level. For example, cytokine IL-1? can mediate the inflammation in innate immunity and promote the proliferation of T and B cells in adaptive immunity.
The rising incidence of autoimmune and autoinflammatory diseases across the world cannot simply be explained by genetic predisposition and better screening programmes. Remarkable environmental alterations and the upsurge in pollution, sleep deprivation, obesity, and a sedative lifestyle are compounding stressors that challenge our immune system. Consequently, patients’ suffering persists, and the economic burden soars.
This is a comprehensive collection of cutting-edge research articles that delve into identifying, validating, and applying biomarkers in diagnosing and managing autoimmune and autoinflammatory disorders. By presenting a curated selection of peer-reviewed research works, the objective of this collection is to provide healthcare professionals and researchers with critical insights into biomarkers in autoimmune and autoinflammatory disease, bringing profound implications for clinical practice and research. By integrating biomarker data into diagnostic and therapeutic strategies, healthcare providers can achieve more precise and personalized patient care. Additionally, these insights can guide future efforts in the development of novel treatment and diagnostic tools.
This collection is intended for a wide audience, including immunologists, rheumatologists, dermatologists, clinical researchers, and medical students. It will serve as a valuable resource for pharmaceutical companies and policymakers involved in healthcare planning and disease management.
This collection welcomes original research or review articles investigating autoimmune/autoinflammatory diseases and related inflammatory conditions, including (but not limited to):
- Novel biomarker discovery and validation for specific diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and ocular conditions.
- Discovery of novel genetic variants associated with disease initiation and/or progression.
- Development of biomarker panels for more accurate and early diagnosis.
- Mechanistic insights into biomarker function.
- Identification of specific biomarkers that can distinguish between different autoimmune and autoinflammatory diseases.
- Discovery of biomarkers that correlate with disease activity and severity.
- Discovery of biomarkers with therapeutic potential, especially with durable efficacy in controlling chronic conditions.
- Predictive biomarkers for treatment responses and disease progression.
- Technological advancements in biomarker detection.
Dr. Jian Liu declares the following conflicts of interest related to this research topic:
Shares in Cirrus Therapeutics and is an inventor listed on the WIPO patent WO2023089151A1.